Veru announces preclinical study results that demonstrate sabizabulin inhibits poxviruses

Sabizabulin inhibited the cell release and cell-to-cell spread of poxvirus in a preclinical study veru further expands study of sabizabulin for the treatment of poxvirus acute respiratory distress syndrome (ards) company plans pre-investigational new drug (ind) meeting with fda to evaluate sabizabulin under the animal rule regulatory pathway for treatment of smallpox virus outbreak miami, fl, april 11, 2023 (globe newswire) -- veru inc. (nasdaq: veru), a biopharmaceutical company focused on developing novel medicines for covid-19 and other viral ards-related diseases and for oncology, today announced results from a preclinical in vitro study evaluating the effects of sabizabulin against prototypical poxvirus, vaccinia virus, which demonstrated that sabizabulin prevented both the release of poxvirus from infected cells and the spread of poxvirus to healthy cells. these preclinical study results support the expansion of sabizabulin's program into additional indications to potentially treat the lethal smallpox virus infection or other related infections if a worldwide emergency outbreak occurs.
VERU Ratings Summary
VERU Quant Ranking